Nymox Reports Positive New Clinical Trial Data on Improvement in Urinary Urgency and Frequency Symptoms in Patients on NX-1207 Drug for Prostate Enlargement
HASBROUCK HEIGHTS, N.J.,Dec. 3, 2008--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reported today positive new data from a recently completed clinical trial of NX-1207, the Company’s investigational drug for BPH. The trial data shows that patients receiving NX-1207 recorded significant quantitative improvement in the important symptoms of urgent need to urinate, and of frequency of urination. Compared to baseline, symptoms of urgency to urinate were reduced by 47% at 90 days after a single treatment with NX-1207 (p< .001), and this improvement was maintained in the majority of patients without further treatment at 12 months (41% improvement, p<.001). Compared to baseline, symptoms of frequency of urination were reduced by 43% at 90 days (p<.001), and this improvement was also maintained without further treatment at one year in the majority of patients (35% improvement, p<.001).
Frequency of urination and the urgent need to go are considered by experts to be two of the symptoms of BPH that cause the greatest degree of bother in men with the condition. Without treatment, these irritative symptoms can progress to other serious problems. NX-1207 has been shown to improve the signs and symptoms of BPH, producing an improvement which has been statistically significantly better than double-blinded placebo and study controls and is higher than the improvement reported for approved drugs for BPH. NX-1207 involves a new targeted approach to the treatment of BPH. The drug is administered by a urologist in an office setting directly into the zone of the prostate where the enlargement occurs, and the injection takes only a few minutes and involves little or no pain or discomfort. NX-1207 has not been found to have the sexual, blood pressure, or other side effects of the approved drugs.
BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age.
More information about Nymox is available at www.nymox.com, email: firstname.lastname@example.org, or 800-936-9669.
This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
For Further Information Contact: Roy Wolvin Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com:
Posted: December 2008